NCT06107803View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

October 13, 2023

Primary Completion Date

January 12, 2024

Study Completion Date

January 12, 2024

Conditions
Negative Symptoms in Schizophrenia
Interventions
DRUG

Roluperidone 64 mg

64 mg/day oral

DRUG

Olanzapine 10 MG

10 mg/day oral

Trial Locations (3)

20877

CBH Health, LLC, Gaithersburg

92845

Collaborative Neuroscience Research, LLC, Garden Grove

08053

Hassman Research Institute, Marlton

Sponsors
All Listed Sponsors
lead

Minerva Neurosciences

INDUSTRY

NCT06107803 - A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia | Biotech Hunter | Biotech Hunter